• Cassava Sciences jumps 16% on meeting with FDA paving the way for phase 3 study of Alzheimer's treatment

    6 days ago - By Business Insider

    Westend61/
    Shares of Cassava Sciences jumped as much as 16% on Monday on news that it successfully completed an end-of-phase two meeting with the FDA for its Alzheimer's treatment Simufilam.
    The biotech company will be moving forward with a pivotal phase-three study in the second half of this year.
    Simufilam is a novel drug that targets "both neuroinflammation and neurodegeneration.
    Sign up here for our daily newsletter, 10 Things Before the Opening Bell
    Shares of Cassava Sciences jumped as much as 16% on Monday on news that the biotech company successfully completed an end-of-phase 2...
    Read more ...